OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS

Equity Capital Raises

Equity Transaction Chart

Viridian publishes weekly data on equity capital raises in the Cannabis/CBD/Psychedelic industries. This data includes information about the company issuing equity (public/private, state/country location), deal size, deal structure, pricing, share information, deal implied valuation, and warrant information.

Week ended 08/25/2023

Week ended 08/25/2023

This Section is Only Available to Higher Tier Memberships

Please Purchase a Premium or Enterprise membership to see more.

Equity Commentary

Viridian publishes weekly insights on equity capital raises in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful equity transactions of that week, and commentary on market conditions, equity deal structures and investor groups.

Week ended 08/25/2023

The Week’s Largest Closed Equity Transaction:

  • On August 21, 2023, Skye Bioscience (SKYE: OTC) completed a PIPE with attached warrants offering for aggregate gross proceeds of $12M.
  • Sky sold 557M units at $.021 per unit. Each unit included one common share and one warrant with a ten-year life and exercise price of $.021(0% premium).
  • The warrant package is worth approximately $.0105 per unit, resulting in a net share price of $.0105, a 50.3% discount to the unit price level. This is the most expensive warrant package we have seen in a transaction of this type. Generally, these transactions include two to three-year warrants with 20-30% exercise premiums. Ten-year warrants, at zero premium, are virtually unheard of. The net result, to be fair, is a net share price not too far off preannouncement level pricing.
  • The transaction, along with the concurrent convertible debt issue, implies a market cap of approximately $58.35M and an enterprise value of $35M. Most importantly, the equity and debt issues significantly increase the company’s liquidity, raising its free cash flow adjusted current ratio from a critically deficient -.6x to an adequate 1.13x. The company expects this liquidity to fund operations through 2024.
  • The lead investors in the transaction were 5 AM Venture Management, LLC, and Versant Ventures.
  • Following the transactions, SKYE intends to conduct a 1:250 reverse split with the goal of uplisting to a senior U.S. exchange.

Public vs. Private Raises: 

  • All three companies that raised capital this week are public—all trade in the U.S. on OTC, and one trades in Canada on the NEO.

Equity vs. Debt Cap Raises: 

  • Equity accounted for 43.0% of this week’s raises.

Week ended 08/25/2023

Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more. 

Weekly Valuation Tracker

Viridian highlights a specific industry sector and provides a deep dive into valuation metrics and comparable company valuations for public companies operating in that sector.  The Weekly Valuation Tracker provides proprietary, actionable valuation data.

This week’s valuation tracker focuses on the 7 U.S. MSOs with market cap over $500M in the Viridian Value Tracker database in gauge the valuation impact of the 2nd earnings that have been released so far, Green Thumb (GTII: CSE), Curaleaf (CURA: CSE), and Trulieve.   

This Chart is Only Available to Higher Tier Memberships

Please Purchase a Premium or Enterprise membership to see more.

Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more. 

This Chart is Only Available to Higher Tier Memberships

Please Purchase a Premium or Enterprise membership to see more.